Diabetes Institute Hides Behind Closed Doors Again
Published Date: 3/31/2025
Notice
Summary
The National Institute of Diabetes and Digestive and Kidney Diseases is holding a private virtual meeting on April 29, 2025, to review special grant applications. This meeting affects researchers seeking funding for diabetes and related health studies, ensuring their ideas stay confidential. No direct money changes are announced, but the decisions could impact future research funding.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Review Could Affect Research Funding
On April 29, 2025, the Special Emphasis Panel will review and evaluate cooperative agreement applications for RFA-DK25-012 HPAP-T1D. The panel's evaluation and funding recommendations could affect researchers seeking NIH cooperative agreements for diabetes and related studies.
Grant Review Closed to Public
The NIH is holding a closed virtual meeting on April 29, 2025, from 1:30 p.m. to 3:30 p.m. to review grant applications (RFA-DK25-012 HPAP-T1D). The meeting is closed under 5 U.S.C. 552b(c)(4) and 552b(c)(6) to protect confidential trade secrets, patentable material, and personal information in applications.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16683, Proposed Collection; 60-Day Comment Request; Data Use Certification for the NIH National Institute on Drug Abuse Data Share Site
The purpose of this notice is to inform the public of the information collection requirement for the NIDA Data Share, the data use terms and conditions, and to request a progress report statement at the time of renewal. In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-16544, Government-Owned Inventions; Availability for Licensing
The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research for the benefit of the public health.
2026-16440, NIH Owned Invention Available for License: Soluble Tissue Factor, a Novel Target, and Antibodies, for Diagnosis, Prevention and Treatment of Thrombosis and Related Conditions
Scientists at the National Cancer Institute (NCI) have discovered a novel therapeutic, diagnostic and prognostic target for thrombosis: Soluble Tissue Factor (sTF). NCI has generated first-in- class antibodies and platform selectively neutralizing pathological coagulation while preserving normal hemostasis. This platform technology can be used to prevent, diagnose and treat pathological thrombosis caused by a variety of clinical conditions-including cancer, sepsis, infectious diseases (e.g., COVID), autoimmune disorders, trauma, heart conditions and inflammatory conditions. It offers a much more sensitive and specific test of thrombosis than the current D-dimer test. It may be applicable to any clinical condition which induces necroptosis, pyroptosis and NETtosis, such as cancer, neurodegenerative disease, ischemia-reperfusion and acute injuries, traumatic injuries, bacterial and viral infections, cardiovascular conditions, and atherosclerosis, inflammatory, autoimmune conditions, and others.
2026-16071, Proposed Collection; 60-Day Comment Request: The Impact of Clinical Research Training and Medical Education at the Clinical Center on Physician Careers in Academia and Clinical Research (Clinical Center)
In compliance with the requirement of the Paperwork Reduction Act of 1995, for opportunity for public comment on proposed data collection projects, the Clinical Center, the National Institutes of Health (NIH) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval.
2026-15565, Proposed Collection; 60-Day Comment Request, Data Use Certification for the NIH Brain Development Cohorts (NBDC) Data Hub, (National Institute on Drug Abuse)
In compliance with the requirement of the Paperwork Reduction Act of 1995 to provide opportunity for public comment on proposed data collection projects, the National Institute on Drug Abuse (NIDA) will publish periodic summaries of proposed projects to be submitted to the Office of Management and Budget (OMB) for review and approval. The purpose of this revision is to update instructions for the Research Data Use Statement and the Progress Report, and to add new instructions for attesting to National Institute of Standards & Technology (NIST) security compliance, and for a Project Close-out at the time of project completion. Burden levels remain unchanged.
2026-14964, Center for Scientific Review; Notice of Closed Meeting
The Center for Scientific Review is holding a closed virtual meeting on August 19, 2026, to review neuroscience career development grant applications. This meeting is private to protect sensitive info like trade secrets and personal details. Researchers applying for these grants should note the date, as funding decisions could impact their projects and careers.
Previous / Next Documents
Previous: 2025-05415, National Institute on Deafness and Other Communication Disorders; Notice of Closed Meeting
The National Institute on Deafness and Other Communication Disorders is holding a private virtual meeting on July 10, 2025, to review special grant applications for clinical research centers. This meeting affects researchers seeking funding and keeps sensitive info safe. No public access means the grant review process stays fair and confidential.
Next: 2025-05417, Thermoformed Molded Fiber Products From the People's Republic of China: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Determination With Final Antidumping Duty Determination; Correction
The U.S. is taking a closer look at certain fiber products from China to make sure fair trade rules are followed. They fixed a small mistake in their earlier report and are lining up their final decisions on extra taxes to keep things fair. This affects Chinese exporters and U.S. buyers, with important updates coming soon on duties and deadlines.